Female hypogonadotropic hypogonadism

Female hypogonadotropic hypogonadism is an endocrine condition characterised by insufficient gonadotropin stimulation of the ovary, resulting in reduced ovarian steroidogenesis, anovulation and inappropriately low or normal levels of FSH and LH in the presence of low estradiol. From a pathophysiological perspective, the primary defect does not lie within the gonad, but within the hypothalamic-pituitary-ovarian axis, where insufficient secretion of GnRH or gonadotropins prevents effective folliculogenesis and normal estrogenic function.

This definition encompasses profoundly different conditions. It includes both congenital forms caused by defects in the development or function of GnRH neurons or in the pituitary secretion of gonadotropins, and acquired or functional forms, in which energy stress, weight loss, excessive physical exercise, systemic diseases, hyperprolactinemia or hypothalamic-pituitary disorders reduce activity of the axis either reversibly or permanently. The clinical impact is not limited to amenorrhea and infertility, but also involves puberty, bone health, sexuality, neuropsychological wellbeing and metabolic risk, which is why particularly rigorous aetiological assessment is required.

The epidemiology of female hypogonadotropic hypogonadism is heterogeneous because it depends on the relative contribution of its different causes. During development, some cases are caused by congenital disorders of the GnRH-gonadotropin axis, which present with absent or incomplete puberty and primary amenorrhea. In young and adult women, however, a substantial proportion of cases consists of functional forms, in which the reproductive system is temporarily suppressed by metabolic or neuroendocrine stress signals. Clinically, the epidemiology of this condition therefore does not correspond to that of a single rare disease, but to that of an endocrine phenotype that may emerge in widely different biological settings.

< b>Congenital forms of isolated hypogonadotropic hypogonadism are less common in women than in men, but they represent a crucial area of reproductive endocrinology because they frequently remain underdiagnosed. When the defect is severe, the patient is assessed because of absent pubertal development or primary amenorrhea. When the defect is partial, incomplete breast development, arrested puberty or secondary amenorrhea after late menarche may occur. This variability reduces the probability of timely recognition, particularly in normosmic forms in which the clinical clue of anosmia is absent.

The principal risk factors for acquired functional forms include low energy availability, caloric restriction, weight loss, intense physical exercise, eating disorders and prolonged psychological stress. The female reproductive system is particularly sensitive to energy deficiency and signals of biological threat, which means that even non-extreme weight loss, when associated with high energy expenditure or individual vulnerability, may suppress GnRH pulsatility. Functional hypothalamic amenorrhea therefore represents one of the most important models of hypogonadotropic hypogonadism in clinical practice.

A second group of risk factors includes acquired organic forms. Hypothalamic-pituitary tumours, craniopharyngioma, adenomas, parasellar lesions, surgery, cranial radiotherapy, head trauma, hypophysitis, infiltrative diseases, haemochromatosis, central nervous system infections and postpartum pituitary necrosis may directly or indirectly impair gonadotropin secretion. In these settings, hypogonadism frequently occurs within a broader pattern of pituitary dysfunction, and its epidemiology is closely linked to that of disorders affecting the hypothalamic-pituitary region.

< b>Hyperprolactinemia, the use of prolactin-raising medications, opioids, glucocorticoids, chronic systemic diseases and certain complex genetic conditions are also relevant risk factors. In patients with chronic disease, the hypogonadotropic phenotype may result from a combination of inflammation, malnutrition, neuroendocrine abnormalities and pharmacological treatment. This makes its epidemiology particularly intertwined with chronic internal medicine disorders and with transition medicine from adolescence to adulthood.

Finally, the epidemiological importance of female hypogonadotropic hypogonadism is increased by its cumulative consequences. A woman who loses physiological activation of the axis during adolescence or young adulthood accumulates years of hypoestrogenism during a stage of life in which peak bone mass, sexual health and fertility should be established. Therefore, even when the underlying cause is potentially reversible, diagnostic delay transforms a theoretically treatable endocrine disorder into a multisystem health problem with tangible prognostic consequences.

Female hypogonadotropic hypogonadism results from dysfunction of the hypothalamic-pituitary-ovarian axis. Under physiological conditions, hypothalamic neurons secrete GnRH in a pulsatile manner, inducing the pituitary gland to release FSH and LH, which in turn support follicular growth, ovarian steroidogenesis, ovulation and menstrual cyclicity. When GnRH pulsatility decreases, or when the pituitary gland fails to secrete gonadotropins adequately, the ovary receives insufficient stimulation and develops ineffective folliculogenesis, anovulation and reduced estradiol production. The resulting biochemical pattern consists of low estradiol with low or inappropriately normal gonadotropins.

From an aetiological perspective, causes can be divided into functional, congenital and acquired organic forms. Functional forms are those in which the anatomical integrity of the axis is preserved, but its activity is suppressed by metabolic or neuropsychological signals. Congenital forms include congenital hypogonadotropic hypogonadism, with or without anosmia, and other syndromes affecting hypothalamic-pituitary development. Acquired organic forms result from tumours, inflammation, trauma, irradiation, infiltrative diseases or pituitary necrosis and are frequently associated with additional anterior pituitary hormone deficiencies.

In functional forms, pathogenesis is closely related to energy availability and the neuroendocrine integration of survival signals. Weight loss, reduced caloric intake, intense physical activity and psychological stress act through hypothalamic networks involving leptin, kisspeptin, orexigenic neuropeptides and stress axes, reducing the frequency and amplitude of GnRH pulses. This suppression lowers LH levels, disrupts follicular recruitment and prevents the normal increase in estrogen production. From this perspective, the reproductive system is temporarily deprioritised in favour of energy requirements perceived by the body as more urgent.

In congenital forms, the mechanism may involve embryonic development of GnRH neurons, their migration from the olfactory placode to the hypothalamus, formation of the higher neuroendocrine networks that regulate their activity or the action of GnRH on the pituitary gland. When the defect is associated with anosmia or hyposmia, it is classically referred to as Kallmann syndrome. When olfaction is preserved, the phenotype may be more difficult to recognise and is often misclassified for a prolonged period as extreme constitutional delay of puberty or idiopathic amenorrhea. Clinical variability depends on the severity of the defect, possible oligogenic inheritance and the presence of associated syndromic phenotypes.

< b>Acquired organic forms interrupt the axis more directly. A sellar or parasellar tumour may compress the pituitary stalk or gland, hypophysitis may selectively damage glandular tissue, radiotherapy may progressively impair hypothalamic-pituitary function, while head trauma or Sheehan syndrome may cause acute or chronic loss of gonadotropin secretion. In these cases, hypogonadism is rarely perfectly isolated, and assessment for other pituitary hormone deficiencies becomes an integral part of the pathophysiological evaluation.

The systemic pathophysiology of secondary hypoestrogenism involves multiple target organs. At the reproductive level, amenorrhea, anovulation, limited pubertal development or arrested puberty occur. At the skeletal level, reduced estrogenic stimulation of remodelling increases the risk of impaired acquisition of peak bone mass or accelerated loss of mineral density. At the genitourinary level, dryness, reduced lubrication and dyspareunia develop. Neuropsychological and metabolic effects may include insomnia, emotional vulnerability, reduced libido and impaired quality of life and, in severe functional forms, interaction with nutritional and stress-related abnormalities. This sequence demonstrates how a central defect produces systemic disease through estrogen deficiency.

The clinical presentation of female hypogonadotropic hypogonadism varies according to age at onset, completeness of the defect and the underlying cause. In severe congenital forms, the typical manifestation is absent or markedly delayed puberty, with limited breast development and primary amenorrhea. In partial or acquired forms, the condition may emerge after a period of normal menstrual cycles, with progressive oligomenorrhea, secondary amenorrhea, infertility or symptoms of hypoestrogenism. The same biological disorder may therefore present either as impaired pubertal development or as acquired loss of reproductive function in a previously eumenorrhoeic woman.

During the medical history, accurate reconstruction of menstrual and pubertal development is essential. The age at breast development, age at menarche, regularity of menstrual cycles, any slowing of pubertal progression, progressive reduction in menstrual frequency and onset of amenorrhea should be established. In functional forms, the consultation should explore changes in body weight, nutritional status, physical training, emotional stress, eating disorders and body image. In organic forms, headache, galactorrhoea, visual disturbances, polyuria, polydipsia, previous neurosurgery, head trauma or irradiation become particularly important.

Symptoms of hypoestrogenism include hot flushes, sweating, sleep disturbances, vaginal dryness, pain during intercourse, reduced libido and mood instability. In young patients, these symptoms are sometimes recognised late because they are perceived as inconsistent with age. Functional forms may also involve fatigue, cold intolerance, reduced physical performance and signs of negative energy balance, while more complex organic forms may be accompanied by features of other pituitary hormone deficiencies.

On physical examination, adolescents may show inadequate breast development, reduced estrogen-dependent trophism and, in the most severe cases, body proportions consistent with prolonged maturational delay. In adult women, findings may be more subtle, although gynaecological examination may reveal hypotrophic mucosa and limited estrogenisation. In functional forms, the phenotype may include low body weight, reduced fat mass or signs of excessive training, although the disorder may also occur in women with an apparently normal weight but relative low energy availability.

The reproductive dimension is often the reason for consultation. Chronic anovulation causes subfertility or infertility, and in congenital forms the problem frequently becomes evident when puberty fails to develop. In acquired forms, infertility may occur in the context of recent amenorrhea or markedly infrequent cycles. In patients with functional hypothalamic disease, reproductive suppression is not merely a gynaecological problem, but indicates a biological adaptation to energy or psychological stress with broader implications for general health.

Over the long term, if the disorder remains unrecognised, reduced bone mass, impaired genitourinary trophism, persistent infertility, psychological distress and relationship difficulties may develop. The clinical picture of female hypogonadotropic hypogonadism should therefore not be interpreted as amenorrhea alone. It is the manifestation of a central defect that profoundly affects multiple domains of women’s health through hypoestrogenism.

Female hypogonadotropic hypogonadism should be suspected in every adolescent with absent or incomplete puberty, in every woman with amenorrhea or persistent oligomenorrhea associated with signs of hypoestrogenism and in every patient with anovulatory infertility whose gonadotropin levels are not appropriately elevated. The central element is recognising that the ovary is not primarily depleted, but is being insufficiently stimulated by an axis that is not functioning appropriately.

Suspicion should increase when amenorrhea and symptoms of estrogen deficiency are associated with weight loss, reduced energy intake, intense athletic activity or severe psychological stress. In these cases, the likelihood of functional hypothalamic amenorrhea is high, but the diagnosis should never be made automatically. It is a diagnosis of exclusion, and pregnancy, pituitary disease, hyperprolactinemia and other organic causes must be excluded before the condition is classified as functional.

Suspicion should be considered particularly strong in patients with anosmia or hyposmia, midline defects, hearing loss, renal agenesis, craniofacial abnormalities or other syndromic features because these findings suggest congenital GnRH deficiency. Similarly, a history of head trauma, sellar surgery, cranial radiotherapy, persistent headache, visual disturbances, polyuria, polydipsia or galactorrhoea requires targeted evaluation for an organic hypothalamic-pituitary cause.

In internal medicine, suspicion should also arise in patients with chronic systemic diseases, eating disorders, multiple endocrine deficiencies, use of prolactin-raising medications or opioids because all these settings may suppress the gonadotropin axis. Amenorrhea in such circumstances should not be considered a secondary detail, but a sign of endocrine dysfunction with important skeletal and reproductive implications.

Finally, clinical suspicion should rapidly lead to diagnostic assessment when the patient wishes to conceive because infertility caused by central dysfunction can often be treated effectively. Delaying evaluation prolongs hypoestrogenism, promotes bone loss and unnecessarily postpones treatments that, particularly in central forms, may restore pubertal development, menstrual cyclicity and fertility more directly than in primary ovarian disorders.

The diagnosis of female hypogonadotropic hypogonadism requires a rational pathway demonstrating a central deficiency of ovarian stimulation and distinguishing functional forms from organic and congenital forms. The first step is to document amenorrhea or marked menstrual irregularity associated with persistently low estradiol and low or inappropriately normal FSH and LH. According to the Society for Endocrinology guideline, a persistently low estradiol concentration below approximately 200 pmol/L in the context of amenorrhea lasting at least 3 months is consistent with female hypogonadism and should prompt serious consideration of the diagnosis, although it is not independently definitive.

In functional forms, the Endocrine Society guideline emphasises that functional hypothalamic amenorrhea can be diagnosed only after anatomical and organic causes have been excluded. Diagnostic reasoning therefore does not end with the identification of low body weight or intense physical activity, but always requires integration of clinical findings, biochemical results and imaging when necessary.

Diagnostic assessment of female hypogonadotropic hypogonadism

• Documentation of amenorrhea, absent puberty or marked menstrual irregularity in a compatible clinical context.
• Demonstration of low estradiol with low or inappropriately normal FSH and LH, after excluding pregnancy and considering any hormone therapies that may conceal the condition.
• Exclusion of the main alternative diagnoses using beta-hCG, TSH, prolactin and assessment of the other pituitary axes when an organic central disorder is suspected.
• Aetiological assessment through nutritional and exercise history, investigation of syndromic features, brain and pituitary MRI when indicated and genetic testing in congenital or suspected congenital forms.

First-line investigations therefore include beta-hCG, FSH, LH, estradiol, TSH and prolactin. Their purpose is to distinguish a central cause from an ovarian cause and promptly identify treatable or diagnostically decisive conditions such as pregnancy and hyperprolactinemia. When signs suggest possible hypopituitarism, the other anterior pituitary axes should also be assessed because gonadotropin deficiency may represent only one component of broader pituitary insufficiency.

The differential diagnosis is central to the assessment. Primary ovarian insufficiency, polycystic ovary syndrome associated with amenorrhea, pregnancy, medication-related amenorrhea, pituitary disease, hyperprolactinemia, chronic systemic disease and eating disorders should be excluded. In particular, a patient with polycystic ovarian morphology should not automatically be classified as having PCOS when estradiol is low and the endometrium is thin because these findings are more suggestive of a central disorder.

< b>Brain and pituitary MRI is not indiscriminately necessary in every patient with suspected functional amenorrhea, but it is indicated when warning signs are present. The Endocrine Society guideline recommends MRI with dedicated pituitary sections and contrast in the presence of severe or persistent headache, persistent non-self-induced vomiting, visual disturbances, unexplained thirst or polyuria, focal neurological signs or clinical and laboratory findings suggestive of deficiency or excess of other pituitary hormones. In these cases, the objective is not only to confirm a sellar lesion, but also to prevent an inappropriate functional diagnosis from concealing a treatable organic disease.

In suspected congenital forms, diagnosis also requires family history, assessment of olfaction, investigation of associated malformations and, when appropriate, genetic testing. Congenital GnRH deficiency is clinically and genetically heterogeneous and may present with syndromic phenotypes or as an apparently isolated reproductive defect. A definitive diagnosis therefore results from the integration of absent or incomplete puberty, low estradiol, non-elevated gonadotropins and localisation of the central defect.

Finally, diagnostic assessment should include evaluation of skeletal and reproductive risk. In patients with prolonged hypoestrogenism, assessment of bone mineral density and nutritional status should be considered because the diagnosis has not only nosological value, but also directly guides prevention of skeletal complications and the strategy for restoring fertility.

The classification of female hypogonadotropic hypogonadism has practical significance because it distinguishes biologically different conditions that share the same laboratory phenotype. The first distinction separates functional from organic forms. In functional forms, the disorder results from adaptive suppression of the axis caused by energy imbalance, psychological stress or exercise. In organic forms, there is a structural or genetic lesion or defect involving the hypothalamus, pituitary gland or GnRH system.

A second classification distinguishes congenital from acquired forms. Congenital forms include congenital hypogonadotropic hypogonadism, Kallmann syndrome and other syndromes involving hypothalamic-pituitary development or multiple hormone deficiencies. Acquired forms include functional hypothalamic amenorrhea, hyperprolactinemia, sellar tumours, hypophysitis, head trauma, Sheehan syndrome, cranial radiotherapy and infiltrative diseases. This distinction is relevant because it changes the potential for reversibility and the probability that other pituitary axes are involved.

From a clinical perspective, it is useful to distinguish forms presenting with primary amenorrhea and absent puberty from those presenting with secondary amenorrhea after initially normal pubertal development. In the first group, the disorder also affects growth, acquisition of peak bone mass and sexual development. In the second, infertility, loss of menstrual cyclicity, symptoms of hypoestrogenism and the psychological impact of functional regression are more prominent.

A further classification concerns the completeness of the defect. In complete forms, puberty may be absent and estrogen levels extremely low. In partial forms, incomplete breast development, late menarche, initially present menstrual cycles and subsequent arrest may occur. This gradation is important because partial forms are also those most readily confused with constitutional delay of puberty, atypical PCOS or amenorrhea caused by other conditions.

< b>Severity should be assessed dynamically and not solely on the basis of hormone levels. Age at onset, duration of hypoestrogenism, degree of pubertal impairment, skeletal risk, presence of organic hypothalamic-pituitary disease, severity of negative energy balance and reproductive goals all matter. A young woman with prolonged functional amenorrhea, low bone mass and an eating disorder has clinically severe disease even in the absence of an anatomical lesion. Similarly, a patient with congenital gonadotropin deficiency and absent puberty has a greater biological and psychological burden than a short-lived acquired form. This assessment of severity is essential because it determines the intensity of monitoring and the urgency of treatment.

Treatment of female hypogonadotropic hypogonadism depends on the cause, but is always based on three objectives: correcting the estrogen deficiency, treating the underlying mechanism and addressing fertility. In functional forms, the initial cornerstone is not pharmacological therapy, but restoration of energy availability and neuroendocrine balance. This requires realignment of caloric intake, physical activity, nutritional status and psychological stress, often through a multidisciplinary approach involving an endocrinologist, gynaecologist, nutritionist and psychological or psychiatric support when necessary.

The Endocrine Society guideline emphasises that treatment of functional hypothalamic amenorrhea should begin with correction of causative factors and that menstrual recovery cannot simply be simulated using oral contraceptives. If the cycle does not resume after a reasonable attempt at nutritional and psychological intervention and modification of exercise, short-term transdermal estradiol combined with a cyclic oral progestogen is suggested, rather than combined contraceptives containing ethinylestradiol as the principal strategy for skeletal protection.

In congenital or permanent organic forms, treatment is replacement-based and should be tailored to age and therapeutic objectives. Adolescents with absent puberty undergo gradual pubertal induction using low doses of estrogen that are progressively increased to allow breast development, uterine maturation and acquisition of bone mass, with subsequent addition of a progestogen in patients with a uterus. In adult women, treatment is based on replacement doses of estradiol, preferably using physiological regimens, combined with a progestogen when required for endometrial protection.

Treatment of acquired organic forms also requires management of the underlying cause. A prolactinoma requires specific dopaminergic treatment, a sellar mass should be treated according to its nature and size, multiple pituitary deficiencies require coordinated replacement of the other axes and infiltrative or inflammatory disease requires targeted aetiological management. In these cases, correcting hypogonadism alone without addressing the underlying disease would be insufficient and potentially dangerous.

< b>Fertility is particularly important because, unlike primary ovarian disorders, infertility caused by central dysfunction can often be treated effectively. In patients seeking pregnancy, the strategy depends on the anatomical level of the defect and the clinical context, but may include exogenous gonadotropins or, less commonly and where available, pulsatile GnRH therapy in hypothalamic forms. This makes reproductive counselling very different from that offered to patients with primary ovarian insufficiency and represents one of the most favourable prognostic aspects of the condition.

Treatment should also include interventions addressing bone health, sexual wellbeing and lifestyle. Adequate calcium and vitamin D intake when indicated, smoking cessation, appropriate but not excessive physical activity, treatment of dyspareunia and psychological support are structural components of care. In patients with migraine with aura or thromboembolic risk, transdermal estradiol regimens are often preferable because of their more physiological and stable profile. The final objective is not simply to restore bleeding, but to re-establish adequate estrogen exposure and protect target organs over the long term.

Follow-up of female hypogonadotropic hypogonadism should verify that treatment is genuinely correcting hypoestrogenism and that the underlying cause is controlled. In functional forms, monitoring should include body weight, energy availability, physical activity, psychological status, menstrual recovery and adherence to nutritional and behavioural interventions. Resumption of menstruation is an important sign, but it should not be considered the sole indicator of recovery when low bone mass, an eating disorder or substantial vulnerability to stress persists.

In patients receiving estrogen therapy, follow-up should assess symptoms, tolerability, pubertal development in adolescents, adequacy of cyclic bleeding when expected and sexual wellbeing. In women with a uterus, appropriate endometrial protection must be confirmed. In permanent forms, therapy should be periodically reassessed to maintain a replacement profile appropriate to age and to changes in the patient’s clinical condition.

< b>Skeletal surveillance is central, particularly when hypoestrogenism has persisted for months or years. Assessment of bone mineral density with DXA should be considered in patients at risk, particularly in prolonged functional forms, adolescents with absent or delayed puberty and women with a history of fractures or severe nutritional deficiency. Skeletal follow-up should not be limited to densitometric findings, but should also include nutritional intake, appropriate physical activity, body weight and the quality of endogenous or replacement estrogen exposure.

In organic hypothalamic-pituitary forms, monitoring should extend to the other endocrine axes and the underlying disease. A patient with an adenoma, hypophysitis or hypopituitarism cannot be followed solely from a reproductive perspective. The corticotropic, thyrotropic and growth hormone axes, neurological status and imaging should be periodically reassessed when indicated because progression of the underlying disease may radically alter gonadotropin function.

< b>Reproductive follow-up should be individualised. When pregnancy is not desired, contraception should be discussed because some central forms, particularly functional or partial forms, may recover ovulation intermittently. When the patient is seeking pregnancy, monitoring should establish the most appropriate timing for ovulation induction, after ensuring adequate nutritional status, a satisfactory overall endocrine profile and the absence of contraindications related to the underlying cause.

Finally, follow-up should include the psychological dimension and quality of life. In functional forms, the risk of recurrence remains substantial unless the underlying energy-related and psychological determinants are fully corrected. In permanent congenital or organic forms, the burden of the diagnosis may accompany the patient for years. High-quality surveillance should therefore integrate body health, fertility, bone health, sexuality and mental wellbeing, avoiding management limited to interpretation of hormone levels alone.

The prognosis of female hypogonadotropic hypogonadism depends decisively on the cause. In functional forms, prognosis may be favourable when the mechanisms suppressing the axis are corrected promptly, with recovery of menstrual cyclicity, fertility and adequate estrogen exposure. In permanent organic or congenital forms, the defect tends to persist and requires prolonged replacement therapy and specific fertility strategies. In both cases, prognosis worsens when diagnosis is delayed and hypoestrogenism persists for years.

The most immediate functional complication is infertility caused by anovulation. However, unlike primary ovarian disorders, reproductive potential in central forms can often be restored with appropriate treatment. This provides a relatively favourable reproductive prognosis, provided that the diagnosis is correct and there are no complex systemic comorbidities or hypothalamic-pituitary lesions limiting the therapeutic pathway.

< b>Skeletal complications represent one of the principal long-term problems. During adolescence, estrogen deficiency impairs acquisition of peak bone mass. In adults, it promotes osteopenia and osteoporosis. In prolonged functional forms, the combination of hypoestrogenism, relative malnutrition and altered mechanical loading may further aggravate skeletal fragility. Reduced mineral density can become clinically relevant even at a young age when the disorder is not corrected.

< b>Sexual and genitourinary complications include vaginal dryness, dyspareunia, reduced libido and impaired relational quality of life. These manifestations are frequently underestimated, but may persist over time even when the patient does not regard amenorrhea as the main problem. In young women, the psychological burden of the diagnosis and infertility may further amplify sexual and emotional impairment.

In organic central forms, prognosis is also influenced by the underlying disease. A sellar tumour, multiple pituitary deficiencies or a hypothalamic lesion alters overall risk far beyond the gonadotropin axis alone and may be associated with neurological, visual or additional endocrine complications. In these cases, hypogonadism is one marker of a broader disorder, and prognosis depends on the ability to manage the entire hypothalamic-pituitary context.

Overall, female hypogonadotropic hypogonadism has a highly variable but often modifiable prognosis. Functional forms may resolve, permanent central forms can be effectively treated with replacement therapy and fertility can frequently be induced successfully. The condition becomes prognostically more serious when it remains unrecognised because skeletal damage, psychological burden and loss of reproductive opportunities progressively accumulate over time.